<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310111</url>
  </required_header>
  <id_info>
    <org_study_id>2013-01-112</org_study_id>
    <nct_id>NCT04310111</nct_id>
  </id_info>
  <brief_title>EUS-RFA for Unresectable Pancreatic Cancer</brief_title>
  <official_title>Efficacy and Safety of Endoscopic Ultrasonography-guided Radiofrequency Ablation in Treatment of Locally Advanced, Unresectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Hangzhou</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for
      pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of
      adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic
      ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with
      unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre-
      and post-procedural clinical data was retrospective collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for
      locally advanced, unresectable PDAC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor size</measure>
    <time_frame>2 years</time_frame>
    <description>Tumor size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of CA19-9</measure>
    <time_frame>2 years</time_frame>
    <description>Serum levels of CA19-9 before and after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>including Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>EUS-RFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients were placed in the lateral position under deep sedation with supplementary oxygen and electrocardiograph monitoring. The target tumor was identified by EUS, then the biopsy needle stylet was removed and replace with the RFA probe. RF energy was applied for 90-120 seconds at 5 Watts. Wait 1 minute before repositioning the Habib™ EUS RFA needle and repeat procedure as many times as needed to ensure complete ablation of the tumor. EUS-guided celiac plexus neurolysis (EUS-CPN) was performed on patients with intractable upper abdominal pain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-RFA</intervention_name>
    <description>Use EUS-RFA to treat unresectable pancreatic cancer</description>
    <arm_group_label>EUS-RFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 20 to 80 years old. ② unresectable PDAC based on review of abdominal
             cross-sectional imaging (CT or MRI) and cytology/ histology results. ③Intolerance to
             chemotherapy due to side effects or patient's comorbidities.

        Exclusion Criteria:

          -  Pregnancy or breast-feeding；②ECOG performance status 3 or 4；③Patients with distant
             metastases or malignant ascites, life expectancy less than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofeng Zhang, M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>First People's Hospital of Hangzhou</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianfeng Yang, M.D</last_name>
    <phone>+86-0571-56006999</phone>
    <email>yjf-1976@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>31006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Yang, M.D</last_name>
      <phone>+86-0571-56006999</phone>
      <email>yjf-1976@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 15, 2020</last_update_submitted>
  <last_update_submitted_qc>March 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First People's Hospital of Hangzhou</investigator_affiliation>
    <investigator_full_name>Jianfeng Yang</investigator_full_name>
    <investigator_title>Associate director of gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>Pancreatic ductal adenocarcinoma</keyword>
  <keyword>Unresectable pancreatic cancer</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Endoscopic ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

